Synexa Life Sciences
Synexa Life Sciences is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjects with advanced-stage, relapsed/refractory solid tumors.
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Synexa Life Sciences?
The 2026-10-09 snapshot links Synexa Life Sciences to 3 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Synexa Life Sciences?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Synexa Life Sciences conducted?
The linked trials record locations in 15 countries, including Spain, Italy, Austria, Belgium, Bulgaria. These are trial locations, not confirmed office locations or countries where Synexa Life Sciences delivered services.
What can this page tell me about Synexa Life Sciences's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Synexa Life Sciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Synexa Life Sciences BV
- Synexa Life Sciences GmbH